Drug Profile
Research programme: ubiquitin-specific protease inhibitors - Almac Discovery/Genentech
Alternative Names: USP7 inhibitorsLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Almac Discovery
- Developer Almac Discovery; Genentech
- Class Antineoplastics; Small molecules
- Mechanism of Action Ubiquitin thiolesterase inhibitors; USP7 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 22 Jun 2020 Pharmacodynamics data from preclinical trials in Cancer presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-2020)
- 18 Jun 2020 Pharmacodynamics data from a preclinical trial in Cancer released by Almac Discovery